

Supplementary Online Content

Neuzil KM, Canh DG, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. *JAMA*. 2011;305(14):1424-1431.

eTable 1. Noninferiority of GMTs post-dose 3 in girls receiving HPV vaccine according to standard and alternative schedules, intention-to-treat population and per-protocol population, mixed model

eTable 2. Number (percent) of participants with at least one unsolicited adverse events reported during days 1 to 7 post-vaccination

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Noninferiority of GMTs Post-dose 3 in Girls Receiving HPV Vaccine According to Standard and Alternative Schedules, Intention-to-Treat Population and Per-Protocol Population^a. Mixed Model

	Adjusted GMT Ratio ^c (98.3% CI)					
	ITT Population			PP Population		
Alternative group Standard group ^b	<u>0, 3, 9</u> 0, 2, 6	<u>0, 6, 12</u> 0, 2, 6	<u>0, 12, 24</u> 0, 2, 6	<u>0, 3, 9</u> 0, 2, 6	<u>0, 6, 12</u> 0, 2, 6	<u>0, 12, 24</u> 0, 2, 6
HPV-16	0.92 (0.65-1.28)	0.97 (0.69-1.36)	0.63 (0.45-0.88)	0.92 (0.65-1.29)	0.97 (0.69-1.36)	0.63 (0.45-0.88)
HPV-18	0.84 (0.63-1.12)	0.88 (0.66-1.18)	0.76 (0.57-1.00)	0.85 (0.63-1.14)	0.89 (0.66-1.19)	0.76 (0.57-1.01)
HPV- 6	1.06 (0.71-1.58)	1.10 (0.74-1.63)	0.64 (0.44-0.94)	1.03 (0.69-1.52)	1.10 (0.75-1.63)	0.63 (0.43-0.92)
HPV-11	0.84 (0.65-1.08)	0.84 (0.66-1.08)	0.95 (0.75-1.22)	0.84 (0.65-1.08)	0.84 (0.66-1.08)	0.95 (0.74-1.21)

^aReceived three doses on schedule, seronegative at baseline, and valid post-dose 3 serology result.

^bFor ITT population, N=206 for 0, 2, 6 group; N=197 for 0, 3, 9 group; N=193 for 0, 6, 12 group; N=213 for 0, 12, 24 group. For PP population, for (1) HPV-16: N=205 for 0, 2, 6 group; N=194 for 0, 3, 9 group; N=193 for 0, 6, 12 group; N=212 for 0, 12, 24 group; (2) HPV-18: N=205 for 0, 2, 6 group; N=195 for 0, 3, 9 group; N=193 for 0, 6, 12 group; N=213 for 0, 12, 24 group; (3) HPV-6: N=203 for 0, 2, 6 group; N=191 for 0, 3, 9 group; N=191 for 0, 6, 12 group; N=207 for 0, 12, 24 group; and (4) HPV-11: N=205 for 0, 2, 6 group; N=195 for 0, 3, 9 group; N=193 for 0, 6, 12 group; N=212 for 0, 12, 24 group.

^cThe results were adjusted for age, ethnicity, and urban/rural residence in a mixed model with study group as a random effect.

eTable 2. Number (Percent) of Participants with at least One Unsolicited Adverse Events Reported During Days 1 to 7 Post-Vaccination

	HPV Vaccination Schedule			
	0, 2, 6 month	0, 3, 9 month	0, 6, 12 month	0, 12, 24 month
N	227	229	206	241
Postdose 1, n (%)	23 (10.1)	30 (13.1)	25 (12.1)	11 (4.6)
N	219	221	199	222
Postdose 2, n (%)	25 (11.4)	16 (7.2)	13 (6.5)	22 (9.9)
N	211	217	196	213
Postdose 3, n (%)	24 (11.4)	25 (11.5)	19 (9.7)	20 (9.4)